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hepatic effects of glucagon (Robison, Butcher & Sutherland, 1971) . The intravenous administration of glucagon causes a rapid increase in the plasma concentration of cyclic AMP, which is thought to be caused by hepatic production of the nucleotide (Broadus, Kaminsky, Northcutt, Hardman, Suther- Insulin antagonizes the effect of glucagon on the formation and release of cyclic AMP in perfused liver of animals in vitro (Park, Lewis & Exton, 1972; Kuster, Zapf & Jakob, 1973) . It has been reported that insulin increases the content of cyclic GMP in various tissues in viho (Illiano, Tell, Siege1 & Cuatrecasas, 1973; Walaas, Walaas & Gronnerod, 1974) . We have investigated whether such actions of insulin in vitro are reftected in changes in the concentration of cyclic nucleotides in human plasma after intravenous injection of insulin alone or in combination with glucagon.
Patients and methods
Subjects studied were from a group of fourteen healthy, non-obese, male volunteers, aged between 19 and 32 years. Basal blood samples were taken after an overnight fast. Insulin (44 nmol; 6 units) and/or glucagon (3,30 or 300 nmol; 10,100 or 1000 lug) were injected into an antecubital vein, and further samples were taken at 5, 15, 30 and 45 min. Paired tests, for example, comparing the effect of glucagon with that of glucagon plus insulin, were carried out on the same subjects on consecutive days.
Blood samples for cyclic nucleotides were taken in sequestrene tubes and kept on ice before separation.
The plasma was deproteinized with an equal volume of trichloroacetic acid (100 g/l), and the acid was removed by shaking with four portions (5 vol.) of water-saturated ether. Samples were stored at -20°C until assay. Cyclic AMP was measured directly by a highly specific radioimmunoassay (Siddle, KaneMaguire & Campbell, 1973) , after addition of CaQz in excess of sequestrene present. Samples for cyclic GMP were absorbed on to 0.4 cm x 2 cm columns of AG-1 X2 resin, 2UOO mesh, chloride form (BioRad Laboratories, Richmond, Calif., USA.). The column was washed with 5 ml of water and 2.5 ml of HCI (50 mmol/l) and then cyclic GMP was eluted with 2-5 ml of HC1 (500 mmol/l). The eluate was freeze-dried and redissolved in assay b&er to give fivefold concentration relative to the original plasma. Recovery of cyclic GMP in this procedure was always greater than 95%. Blood glucose was measured by a standard glucose oxidase Auto-analyzer method (Boehringer Corp., London). Statistical significance of differences was assessed by Student's t-test or paired t-test, as appropriate.
Mean fasting concentrations from all tests in the current study were: blood glucose 4.0 kO.1 mmol/l (mean f SEM, forty-four tests); plasma cyclic AMP 28 2 2 nmol/l (forty-four tests); plasma cyclic GMP The concentrations of both cyclic AMP and cyclic GMP in plasma were measured after the injection of insulin or after a control injection of sodium chloride solution (150 mmol/l; saline). Cyclic AMP concentration ( Fig. 1) fell by 17% over 45 min in the control test (Pt0-01). The reason for this fall is unknown. After insulin, cyclic AMP concentration fell by 16% at 15 min and although this was a greater fall than that observed 15 min after the saline infusion, the difference was not statistically significant (P>O.O5). At 30 and 45 min after insulin injection, there was a highly significant rise (Pt0.001) in plasma cyclic AMP concentration to more than twice the initial value. Cyclic GMP concentration (Fig. 1) was slightly elevated at all time points after insulin, but at no time was the difference statistically significant (P>0.05) from the values observed after injection of saline.
In a separate test on three of the subjects (results not shown), injection of insulin was followed by an infusion of glucose [lo0 ml of 0.55 mol/l (10%) solution over 30 rnin], which lessened the hypoglycaemic effect of insulin and prevented hypoglycaemic symptoms. No effect of insulin on plasma cyclic nucleotide concentrations was observed under these conditions, and the rise in cyclic AMP at 30 and 45 rnin after insulin was prevented.
Injection of glucagon caused a dose-dependent rise in the concentration of plasma cyclic AMP. Glucagon doses used in the present work (3 or 30 nmol, Fig. 2) were submaximal relative to the dose of 300 nmol(1 mg) used in a previous study (Elkeles, Lazarus, Siddle &Campbell, 1975a), which produced a twentyto forty-fold increase in plasma cyclic AMP. The increase in blood glucose produced after 300 nmol of glucagon was greater than that seen after 3 nmol, but not significantly different from that after 30 nmol of glucagon.
, Or T The effect of insulin on the glucagon-induced rise in plasma cyclic AMP was tested in subjects who received glucagon alone or glucagon and insulin simultaneously, on successive days. Insulin (44 nmol) had no significant effect on the concentration of cyclic AMP at 5 and 15 min produced by 3 or 30 nmol of glucagon (Fig. 2) . The mean values ( f SEM) for ratios of plasma cyclic AMP concentrations with insulin/without insulin, calculated from the paired values for each subject, were: 30 nmol of glucagon: 5 min, 0.91 k0.08; 15 min, 1.11 k0.22; 3 nmol of glucagon : 5 min, 0.94 k 0.08 ; 15 min, 0.93 k 0.04.
With 44 nmol of insulin plus 3 nmol of glucagon, there was a second rise in cyclic AMP at 30 min (Fig. 2) (Pt0.02 relative to glucagon alone at 30 min and relative to glucagon plus insulin at 15 min) similar to that occurring at this time with insulin alone (Fig. 1) .
After injection of insulin with glucagon, there was a sharp fall in blood glucose concentration, with maximal hypoglycaemia at 30 min. However, this was preceded in every subject by a small rise in blood glucose at 5 rnin (Fig. 2) . However, insulin had no significant effect on plasma cyclic AMP or cyclic GMP concentrations in the fist 15 min after injection in man (Fig. 1 ). An increase in cyclic AMP which occurred 30 rnin after injection (Fig. 1) was prevented by glucose infusion and was probably caused by an increase in the secretion of glucagon found no significant changes in the urinary excretion of cyclic AMP and cyclic GMP after elevation of endogenous insulin secretion during glucose-tolerance tests, and reported a twofold increase in cyclic AMP excretion during the hypoglycaemia of a single insulin-tolerance test.
When insulin (44 nmol) was injected together with submaximal glucagon doses (3 or 30 nmol), it did not significantly affect theglucagon-induced rise in plasma cyclic AMP (Fig. 2) , which is thought to originate from the liver (Broadus et al., 1970 ; Strange & Mjos, 1975) . Also, insulin did not prevent a small transient hyperglycaemic effect of glucagon (Fig. 2) , suggesting that a stimulation of hepatic glucose output was still occurring. There was thus no clear evidence for a direct hepatic effect of insulin in vivo when it was injected at up to fifteenfold molar excess over glucagon. The effective concentration ratio acting on the liver may not be the same as the ratio injected owing to contributions from endogenously secreted hormones and differential destruction of the two hormones. Half-times for removal of insulin and glucagon from plasma appear to be similar, values in the range 4-10 min having been reported for both hormones (Unger & Eisentraut, 1967; Orksov & Christensen, 1969; Turner, Grayburn, Newman & Nabarro, 1971), although it has been suggested that glucagon is the more rapidly removed from plasma (Assan, 1972) .
Endogenous insulin/glucagon ratios in man have been reported to vary from 0.4 in starvation up to 16 after glucose infusion (Unger, 1972) . These values may not accurately reflect those in portal blood, and the effects of different insulin/glucagon ratios on liver metabolism in man are unknown. The insulin/ glucagon ratios used to demonstrate hepatic effects of insulin in vitro vary widely. In rat liver, effects of insulin on carbohydrate metabolism have been shown with ratios of 0.04 (Parrilla, Toews & Goodman, 1972) 1973). The insulin/glucagon ratios of 1.5 and 15 used in the present study (Fig. 2) appear to fall within the expected physiological range for man and also within the range effective in the rat. Injection of greater amounts of insulin was not possible without use of glucose, and smaller amounts of glucagon would not give an easily detectable plasma cyclic AMP response, so that it would be difficult to investigate the effects of still higher insulin/glucagon ratios in man.
It is concluded that insulin does not have a significant acute effect on cyclic nucleotide concentrations in normal men. The long-term effects of insulin have been investigated by measurement of hepatic cyclic AMP release (Liljenquist et al., 1974) or peripheral plasma cyclic AMP concentration (Elkeles, Siddle, Shetty & Lazarus, 1975b) after glucagon infusion in diabetic subjects. In both cases the diabetic subjects did not show a significant difference from the control response. It therefore appears that plasma cyclic nucleotides do not provide an index of short-or long-term tissue sensitivity to insulin.
